AOTMiT: What will the Transparency Council address at its upcoming meeting?

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Amvuttra (vutrisiran) under the drug program: "Treatment of adult patients with stage I or II polyneuropathy in the course of hereditary transthyretin amyloidosis (ICD-10 E85.1)".
2. Preparation of a position paper on the evaluation of the drug Abrysvo (respiratory syncytial virus (RSV) vaccine, bivalent, recombinant) for the indication: active immunization of people aged 60 years and older against lower respiratory tract diseases caused by RSV.
3. Preparation of a position paper on the evaluation of the drug Abrysvo (syncytial respiratory virus (RSV) vaccine, bivalent, recombinant) for the indication: passive protection against lower respiratory tract diseases caused by syncytial respiratory virus (RSV) in infants from birth to 6 months of age after maternal vaccination during pregnancy.
4. Preparation of a position paper on the examination of the appropriateness of issuing reimbursement approvals for the foodstuff for special nutritional use FruitiVits for the indication: Dietary supplementation of vitamins and minerals in glutaraldehyde type I aciduria, isovalerate aciduria, methylmalonic aciduria, propionate aciduria, pyruvate dehydrogenase deficiency, adenylsuccinate lyase deficiency, argininosuccinate lyase deficiency, carbamylphosphate synthase (CPS1) deficiency, OTC deficiency, NAGS deficiency, citrulinemia, LCHAD deficiency, type I glucose transporter deficiency, drug-resistant epilepsy, Leigh syndrome, homocystinuria, glycogenosis, tyrosinemia.

Source: AOTMiT